Effects of the route of oestrogen administration on IGF-1 and IGFBP-3 in healthy postmenopausal women: Results from a randomized placebo-controlled study

Clinical Endocrinology

Volumn 66, Issue 5, 2007, Pages 626-631

  Sonnet, Emmanuel ^a   Lacut, Karine ^a   Roudaut, Nathalie ^a   Mottier, Dominique ^a   Kerlan, Véronique ^a   Oger, Emmanuel ^a  

^a SERVICE DE RHUMATOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; GROWTH HORMONE; PLACEBO; PROGESTERONE; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; HORMONE SUBSTITUTION; HUMAN; NORMAL HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; AGED; BIOLOGICAL MARKERS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MIDDLE AGED; POSTMENOPAUSE; PROGESTERONE; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 34247842823     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2007.02783.x     Document Type: Article

References (38)

1. Hulley, S., Grady, D., Bush, T., Furberg, C., Herrington, D., Riggs, B. Vittinghoff, E. (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Journal of the American Medical Association, 280, 605 613.
2. Rossouw, J.E., Anderson, G.L., Prentice, R.L., LaCroix, A.Z., Kooperberg, C., Stefanick, M.L., Jackson, R.D., Beresford, S.A., Howard, B.V., Johnson, K.C., Kotchen, J.M. Ockene, J. Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. Journal of the American Medical Association, 288, 321 333.
3. Lacut, K., Oger, E., Le Gal, G., Blouch, M.T., Abgrall, J.F., Kerlan, V., Scarabin, P.Y. Mottier, D. SARAH Investigators (2003) Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein. Thrombosis and Haemostasis, 90, 124 131.
4. Conti, E., Carrozza, C., Capoluongo, E., Volpe, M., Crea, F., Zuppi. C. Andreotti, F. (2004) Insulin-like growth factor-1 as a vascular protective factor. Circulation, 110, 2260 2265.
5. Juul, A., Scheike, T., Davidsen, M., Gyllenborg, J. Jorgensen, T. (2002) Low serum insulin-like growth factor 1 is associated with increased risk of ischemic heart disease. A population-based control study. Circulation, 106, 939 944.
6. Laughlin, G.A., Barrett-Connor, E., Criqui, M.H. Kritz-Silverstein, D. (2004) The prospective association of serum insulin-like growth factor 1 (IGF-1) and IGF-binding protein 1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. Journal of Clinical Endocrinology and Metabolism, 89, 114 120.
7. Vasan, R.S., Sullivan, L.M., D'Agostino, R.B., Roubenoff, R., Harris, T., Sawyer, D.B., Levy, D. Wilson, P.W.F. (2003) Serum insulin-like growth factor-1 and risk of heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study. Annals of Internal Medicine, 139, 642 648.
8. Johnsen, S.P., Hundborg, H.H., Sorensen, H.T., Orskov, H., Tjonneland, A., Overvad, K. Jorgensen, J.O.L. (2005) Insulin-like growth factor (IGF) I-II, and IGF binding protein-3 and risk of ischemic stroke. Journal of Clinical Endocrinology and Metabolism, 90, 5937 5941.
9. Leung, K.C., Johannsson, G., Leong, G.M. Ho, K.K. (2004) Estrogen regulation of growth hormone action. Endocrine Review, 25, 693 721.
10. Weissberger, A.J., Ho, K.K. Lazarus, L. (1991) Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor 1, and GH-binding protein in postmenopausal women. Journal of Clinical Endocrinology and Metabolism, 72, 374 381.
11. Nugent, A.G., Leung, K.C., Sullivan, D., Reutens, A. Ho, K.K.Y. (2003) Modulation by progestogens of the effects of estrogen on hepatic endocrine function in postmenopausal women. Clinical Endocrinology, 59, 690 698.
12. Campagnoli, C., Abbà, C., Ambroggio, S. Peris, C. (2003) Differential effects of progestins on the circulating IGF-I system. Maturitas, 46 (Suppl. 1 S39 S44.
13. Oger, E., Alhene-Gelas, M., Lacut, K., Blouch, M.T., Roudaut, N., Kerlan, V., Collet, M., Abgrall, J.F., Aiach, M., Scarabin, P.Y. Mottier, D. SARAH Investigators (2003) Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arteriosclerosis, Thrombosis, and Vascular Biology, 23, 1671 1676.
14. Blum, W.F. Schweizer, R. (2003) Insulin-like growth factors and their binding proteins. In : M.B. Ranke ed. Diagnostics of Endocrine Function in Children and Adolescents. Karger, Basel, 166 199.
15. Helle, S.I., Omsjo, I.H., Hughes, S.C., Botta, L., Hulls, G., Holly, J.M. Lonning, P.E. (1996) Effects of transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: a cross-over study. Clinical Endocrinology, 45, 727 732.
16. Cano, A., Castelo-Branco, C. Tarin, J.J. (1999) Effect of menopause and different combined estradiol-progestin regimens on basal and growth hormone-releasing hormone-stimulated serum growth hormone, insulin-like growth factor-1, insulin-like growth factor binding protein (IGFBP)-1 and IGFBP-3 levels. Fertility and Sterility, 71, 261 267.
17. Karjaleinen, A., Paassilta, M., Heikkinen, J., Backstrom, A.C., Savolainen, M. Kesaniemi, Y.A. (2001) Effects of peroral and transdermal estrogen replacement therapy on glucose and insulin metabolism. Clinical Endocrinology, 54, 165 173.
18. Paassilta, M., Karjalainen, A., Kervinen, K., Savolainen, M.J., Heikkinen, J., Backstrom, A.C. Kesaniemi, Y.A. (2000) Insulin-like growth factor binding protein-1 (IGFBP-1) and IGF-1 during oral and transdermal estrogen replacement therapy: relation to lipoprotein(a) levels. Atherosclerosis, 149, 157 162.
19. Kam, G.Y.W., Leung, K.C., Baxter, R.C. Ho, K.K.Y. (2000) Estrogens exert route and dose-dependent effects on insulin-like growth factor (IGF) binding protein-3 and the acid-labile subunit of the IGF ternary complex. Journal of Clinical Endocrinology and Metabolism, 85, 1918 1925.
20. Decensi, A., Bonanni, B., Baglietto, L., Guerrieri-Gonzaga, A., Ramazotto, F., Johansson, H., Robertson, C., Marinucci, I., Mariette, F., Sandri, M.T., Daldoss, C., Bianco, V., Buttarelli, M., Cazzniga, M., Franchi, D., Cassano, E. Omodei, U. (2004) A two-by-two factorial trial comparing oral with transdermal estrogen therapy and fenretinide with placebo on breast cancer biomarkers. Clinical Cancer Research, 10, 4389 4397.
21. Vongpatanasin, W., Tuncel, M., Wang, Z., Arbique, D., Mehrad, B. Jiala, I. (2003) Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. Journal of the American College of Cardiology, 41, 1358 1363.
22. Ravn, P., Overgaard, K., Spencer, E.M. Christiansen, C. (1995) Insulin-like growth factors 1 and 2 in healthy women with and without established osteoporosis. European Journal of Endocrinology, 132, 313 319.
23. Garnero, P., Tsouderos, Y., Marton, I., Pelissier, C., Varin, C. Delmas, P. (1999) Effects of intranasal 17β-estradiol on bone turnover and serum insulin-like growth factor 1 in postmenopausal women. Journal of Clinical Endocrinology and Metabolism, 84, 2390 2397.
24. Herrington, J. Carter-Su, C. (2001) Signaling pathways activated by the growth hormone receptor. Trends in Endocrinology and Metabolism, 12, 252 257.
25. Metcalf, D., Greenhalgh, C.J., Viney, E., Willson, T.A., Starr, R., Nicola, N.A., Hilton, D.J. Alexander, W.S. (2000) Gigantism in mice lacking suppressor of cytokine signaling-2. Nature, 405, 1069 1073.
26. Leung, K.C., Doyle, N., Ballesteros, M., Sjogren, K., Watts, C.K.W., Low, T.H., Leong, G.M., Ross, R.J.M. Ho, K.K.Y. (2003) Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2. Proceedings of the National Academy of Sciences of the United States of America, 100, 1016 1021.
27. Friend, K.E., Hartman, M.L., Pezzoli, S.S., Clasey, J.L. Thorner, M.O. (1996) Both oral and transdermal estrogen increase growth hormone release in postmenopausal women - a clinical research center study. Journal of Clinical Endocrinology and Metabolism, 81, 2250 2256.
28. Veldhuis, J.D., Anderson, S.M., Patrie, J.T. Bowers, C.Y. (2004) Estradiol supplementation in postmenopausal women doubles rebound-like release of growth hormone (GH) triggered by sequential infusion and withdrawal of somatostatin: evidence that estrogen facilitates endogenous GH-releasing hormone drive. Journal of Clinical Endocrinology and Metabolism, 89, 121 127.
29. Mah, P.M., Webster. J., Jönsson, P., Feldt-Rasmussen, U., Koltowska-Häggstrom, M. Ross, R.J.M. (2005) Estrogen replacement in women of fertile years with hypopituitarism. Journal of Clinical Endocrinology and Metabolism, 90, 5964 5969.
30. Rosen, T. Bengtsson, B.A. (1990) Premature mortality due to cardiovascular disease in hypopituitarism. Lancet, 336, 285 288.
31. Janssen, J.A., Stolk, R.P., Pols, H.A., Grobbee, D.E. Lamberts, S.W. (1998) Serum free and total IGF-1, free IGF-1 and IGFBP-1 levels in an elderly population: relation to cardiovascular risk factors and disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 18, 277 282.
32. Baxter, R.C. (2003) Circulating binding proteins for the insulin-Iike growth factors. Trends in Endocrinology and Metabolism, 4, 91 95.
33. Ho, K.K.Y., O'Sullivan, A.J., Wolthers, T. Leung, K.C. (2003) Metabolic effects of oestrogens: impact of the route of administration. Annals of Endocrinology, 64, 170 177.
34. Heald, A., Selby, P.L., White, A. Gibson, J.M. (2000) Progestins abrogate estrogen-induced changes in the insulin-like growth factor axis. American Journal of Obstetrics and Gynecology, 183, 593 600.
35. Bellantoni, M.F., Vittone, J., Campfield, A.T., Bass, K.M., Harman, S.M. Blackman, M.R. (1996) Effects of oral versus transdermal estrogen on the growth hormone/insulin-like growth factor 1 axis in younger and older postmenopausal women: a clinical research center study. Journal of Clinical Endocrinology and Metabolism, 81, 2848 2853.
36. Vestergaard, P., Hermann, A.P., Orskov, H. Mosekilde, L. (1999) Effect of sex hormone replacement therapy on the insulin-like growth factor system and bone mineral: a cross-sectional and longitudinal study in 595 perimenopausal women participating in the Danish Osteoporosis Prevention Study. Journal of Clinical Endocrinology and Metabolism, 84, 2286 2290.
37. Cardim, H.J.P., Lopes, C.M.C., Giannella-Neto, D., Maggio da Fonseca, A. Pinotti, J.A. (2001) The insulin-like growth factor 1 system and hormone-replacement therapy. Fertility and Sterility, 75, 282 287.
38. Biglia, N., Ambroggio, S., Ponzone, R., Sgro, L., Ujcic, E., Actis Dato, F. Sismondi, P. (2003) Modification of serum IGF-I, IGFBPs and SHBG levels by different HRT regimens. Maturitas, 45, 283 291.